Avatar photo

Dr. Kris Kowdley

Dr. K. Kowdley -USA

Natural history and clinical outcomes in adults with NAFLD – lessons from cohort studies and placebo arms of trials

It was found that the natural history of NAFLD is variable. Whilst 31% of patients with NAFLD develop NASH, 29% of patients have been found to resolve it. The fibrosis progression rate in clinical trials stands at ~20%. The rate of improvement for fibrosis patients stands at ~22% and results are driven by factors such as regression to the mean, sampling variability and observer variability. The placebo response was also determined by the same variables mentioned above. Advanced fibrosis (F3 and F4) act as drivers for clinical outcomes. 10% IR was also found in the new decompensation in advanced NASH.
Read More

Dr. Kowdley received his BS in Biology and Anthropology as a member of the Dean’s List at Columbia University, and his medical degree from Mount Sinai School of Medicine. He completed his internship and residency at Oregon Health Science University and a Fellowship in Gastroenterology and Hepatology at Tufts University School of Medicine.Dr. Kowdley has extensive experience in clinical trials in all areas of liver disease, ranging from hepatitis C, cholestatic liver disease, PBC, PSC, nonalcoholic steatohepatitis and hepatitis B. He has been a principal investigator in several NIDDK-sponsored clinical trials in primary biliary cirrhosis, primary sclerosing cholangitis and is a member of executive committee of the nonalcoholic steatohepatitis clinical research network (NASH CRN). Dr. Kowdley’s research program has been continuously funded by the NIDDK since 1999 in addition to several grants from foundations and scientific societies.